1009 Results

People

  1. Motzer
    Motzer
  2. O'Reilly
    O'Reilly
  3. Kris
    Kris
  4. Aghajanian
    Aghajanian
  5. Hudis
    Hudis
  6. Bajorin
    Bajorin
  7. Kelsen
    Kelsen
  8. Ginsberg
    Ginsberg
  9. Krug
    Krug
  10. Scher
    Scher

Groups

  1. Department of Medicine (716)
  2. Solid Tumor Oncology Division (483)
  3. Hematologic Malignancies, Division of (277)
  4. Center for Hematologic Malignancies (224)
  5. Survivorship Research (151)
  6. Genitourinary Oncology Service (136)
  7. Epidemiology and Biostatistics (119)
  8. Radiology, Department of (111)
  9. Biostatistics Service (109)
  10. GSK Faculty (104)
  1. "anemia"
Formats
  1. Journal Article (926)
  2. Review (42)
  3. Research Letter (15)
  4. Conference Paper (12)
  5. Editorial (4)
  6. Guidelines (3)
  7. Miscellaneous (3)
  8. Correspondence (2)
  9. Book Section (1)
  10. Meeting Abstract (1)
Groups
  1. Department of Medicine (716)
  2. Solid Tumor Oncology Division (483)
  3. Hematologic Malignancies, Division of (277)
  4. Center for Hematologic Malignancies (224)
  5. Survivorship Research (151)
  6. Genitourinary Oncology Service (136)

More Groups

People
  1. Robert Motzer (55)
  2. Eileen O'Reilly (35)
  3. Mark Kris (32)
  4. Carol Aghajanian (31)
  5. Clifford Hudis (31)
  6. Dean Bajorin (29)

More People

Years
  1. 2025 (41)
  2. 2024 (99)
  3. 2023 (56)
  4. 2022 (45)
  5. 2021 (25)
  6. 2020 (62)

More Years

Publications
  1. Journal of Clinical Oncology (69)
  2. Cancer (50)
  3. Clinical Cancer Research (49)
  4. Lancet Oncology (47)
  5. Gynecologic Oncology (34)
  6. Blood (29)

More Publications

Publishers
  1. Elsevier Inc. (147)
  2. Springer (90)
  3. Elsevier Science, Inc. (83)
  4. American Society of Clinical Oncology (74)
  5. Wiley Blackwell (65)
  6. Nature Publishing Group (61)

More Publishers

Results (1009)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial
    Journal Article

    Wainberg, Z. A.; Melisi, D.; Macarulla, T.; Pazo Cid, R.; Chandana, S. R.; De La Fouchardière, C.; Dean, A.; Kiss, I.; Lee, W. J.; Goetze, T. O.; more...
    Lancet (2023)

    Fulltext@MSK | Save
  • A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer
    Journal Article

    Han, S. N.; Oza, A.; Colombo, N.; Oaknin, A.; Raspagliesi, F.; Wenham, R. M.; Braicu, E. I.; Jewell, A.; Makker, V.; Krell, J.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • ILUSTRO: Phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2–positive gastric or gastroesophageal junction adenocarcinoma
    Journal Article

    Klempner, S. J.; Lee, K. W.; Shitara, K.; Metges, J. P.; Lonardi, S.; Ilson, D. H.; Fazio, N.; Kim, T. Y.; Bai, L. Y.; Moran, D.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Randomized phase 2 clinical trial of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcomas
    Journal Article

    Attia, S.; Villalobos, V.; Hindi, N.; Wagner, A. J.; Chmielowski, B.; Oakley, G. J. 3rd; Peterson, P. M.; Ceccarelli, M.; Jones, R. L.; Dickson, M. A.
    Cancers (2023)

    Fulltext@MSK | Save
  • Acute leukemia with predominantly myeloid differentiation and TBL1XR1::CSF1R fusion
    Miscellaneous

    Kumar, J.; Petrova-Drus, K.
    Blood (2023)

    Fulltext@MSK | Save
  • Current advances in 2022: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies (AABB) Clinical Transfusion Medicine Committee
    Review

    Metcalf, R. A.; Cohn, C. S.; Bakhtary, S.; Gniadek, T.; Gupta, G.; Harm, S.; Haspel, R. L.; Hess, A. S.; Jacobson, J.; Lokhandwala, P. M.; more...
    Transfusion (2023)

    Fulltext@MSK | Save
  • Comparison of short-term outcomes and survival between minimally invasive colectomy and open colectomy in patients 80 years of age and older
    Journal Article

    Thompson, H. M.; Williams, H.; Omer, D. M.; Yuval, J. B.; Verheij, F. S.; Fiasconaro, M.; Widmar, M.; Wei, I. H.; Pappou, E. P.; Smith, J. J.; more...
    Journal of Robotic Surgery (2023)

    Fulltext@MSK | Save
  • Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: Final results from the phase 2 TRITON2 study
    Journal Article

    Abida, W.; Campbell, D.; Patnaik, A.; Bryce, A. H.; Shapiro, J.; Bambury, R. M.; Zhang, J.; Burke, J. M.; Castellano, D.; Font, A.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
    Review

    Pegram, M.; Pietras, R.; Dang, C. T.; Murthy, R.; Bachelot, T.; Janni, W.; Sharma, P.; Hamilton, E.; Saura, C.
    Therapeutic Advances in Medical Oncology (2023)

    Fulltext@MSK | Save
  • Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis
    Review

    Kubeczko, M.; Jarząb, M.; Gabryś, D.; Krzywon, A.; Cortez, A. J.; Xu, A. J.
    Radiotherapy and Oncology (2023)

    Fulltext@MSK | Save